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Long-term outcomes of Omniflow II biosynthetic vascular graft in 
lower extremity arterial revascularization
Omniflow II biyosentetik vasküler greftin alt ekstremite arteriyel revaskülarizasyonunda
uzun dönem sonuçları
Faruk Toktaş1, Mustafa Çağdaş Çayır2, Kadir Kaan Özsin1, Şenol Yavuz1, Mehmet Tuğrul Göncü1
ÖZ
Amaç: Bu çalışmada tıkayıcı damar hastalığı olan hastalarda 
Omniflow II biyosentetik vasküler greftler ile femoropopliteal 
baypas işlemlerinin açıklık oranı ve uzun dönem sonuçları 
değerlendirildi.
Ça­lış­ma­ pla­nı:­ Bu retrospektif, gözlemsel, klinik çalışmaya 
periferik arter hastalığı nedeniyle Omniflow II biyosentetik 
vasküler greftlerin kullanıldığı femoropopliteal baypas yapılan 
toplam 93 hasta (61 erkek, 32 kadın; ort. yaş 56.9±7.4 yıl; dağılım, 
43-83 yıl) alındı. Bu hastalar iki gruba ayrıldı: femoropopliteal 
diz üstü baypas yapılan 62 hasta ve femoropopliteal diz altı 
baypas yapılan 31 hasta. Ameliyat öncesi klinik özellikler, 
ameliyat sonrası greft açıklık oranları ve diğer klinik bulgular 
değerlendirildi.
Bul gu lar: Ortalama takip süresi femoropopliteal diz üstü 
baypas grubunda 44.9±18.8 ay ve femoropopliteal diz altı 
baypas grubunda 47.3±22.3 ay idi (p=0.302). Üç, dört ve beşinci 
yıllarda femoropopliteal diz üstü baypas ve femoropopliteal 
diz altı baypas grubunda kümülatif primer greft açıklık 
oranları sırasıyla %98, %95 ve %78 ve %86, %75 ve %45 idi 
(log-rank; p=0.312). Beşinci yılda femoropopliteal diz üstü 
baypas ve femoropopliteal diz altı baypas grubunda kümülatif 
yardımlı greft açıklık oranları sırasıyla %87.9 ve %65.3 idi 
(log-rank; p=0.530).
So­nuç:­Omniflow II biyosentetik vasküler greft, femoropopliteal 
diz üstü ve diz altı baypas işlemlerinde kullanılabilir. Bu greftler 
yüksek açıklık oranları, düşük anevrizma ve enfeksiyon gelişim 
insidansı nedeniyle tercih edilebilir.
Anah­tar­söz­cük­ler: Biyosentetik greft; açıklık; revaskülarizasyon.
ABSTRACT
Background:­ This study aims to evaluate the patency rates and 
long-term outcomes of femoro-popliteal bypass procedures with 
Omniflow II biosynthetic vascular grafts in patients with occlusive 
vascular disease.
Methods: This retrospective, observational, clinical study included 
a total of 93 patients (61 males, 32 females; mean age 56.9±7.4 
years; range, 43 to 83 years) who underwent femoro-popliteal 
bypass in which Omniflow II biosynthetic vascular grafts were used 
due to peripheral arterial disease. The patients were divided into 
two groups: 62 patients undergoing femoro-popliteal above-knee 
bypass and 31 patients undergoing the femoro-popliteal below-
knee bypass. We evaluated preoperative clinical characteristics, 
postoperative graft patency rates, and other clinical results.
Results:­The mean follow-up was 44.9±18.8 months in the femoro-
popliteal above-knee bypass group and 47.3±22.3 months in 
the femoro-popliteal below-knee bypass group (p=0.302). The 
cumulative primary graft patency rates of the femoro-popliteal 
above-knee bypass and femoro-popliteal below-knee bypass groups 
at three, four, and five years were 98%, 95% and 78% and 86%, 75% 
and 45%, respectively (log-rank; p=0.312). The cumulative assisted 
graft patency rates of the femoro-popliteal above-knee bypass and 
femoro-popliteal below-knee bypass groups at five years were 
87.9% and 65.3%, respectively (log-rank; p=0.530).
Conclusion:­The Omniflow II biosynthetic vascular graft is suitable 
for above- and below-knee femoro-popliteal bypass procedures. 
These grafts may be prefered due to high patency rates, low 
incidence of aneursym formations, and infections.
Keywords: Biosynthetic graft; patency; revascularization.
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Numerous graft materials have been in general use 
for arterial reconstructive procedures since the 1950s. 
Over the years, considerable effort has been directed 
to the development of artificial vessels that provide 
equivalent or better results than autogenous vessels, but 
without success.[1,2]
Despite their superior performance, autogenous 
vein grafts are not often available in an estimated 
30% of total vascular procedures, and this rate rises 
up to 50% in patients undergoing secondary vascular 
procedures. When available, many surgeons are 
reluctant to use a greater saphenous vein for above-
knee revascularization due to the potential future 
requirements for a more distal below-knee or coronary 
artery revascularization procedure.
Although patients’ clinical situations differ mostly, 
the success of an alternative prosthetic graft, either 
synthetic or biological, is reliant upon both the 
thrombogenic properties of the flow surface and the 
host’s reaction to the graft material.
Synthetic grafts manufactured from expanded 
polytetrafluoroethylene (ePTFE) or polyester, some 
modified with anti-coagulants and anti-microbial 
agents, are the most commonly used grafts for medium 
and larger diameter vascular bypass.[3-5] Although most 
synthetic material grafts >6 mm internal diameter 
provide adequate function as a blood conduit, their 
function is limited in small diameter, low flow (<6 mm) 
applications.[6] To date, neither synthetic nor alternative 
grafts of biological origin have demonstrated better 
performance than autogenous vessels and the search 
for the “ideal” bypass conduit continues. Biological 
grafts derived from either homogenous or xenogenous 
sources are commonly cross-linked with glutaraldehyde 
to provide the non-antigenic blood conduits widely 
used over the past 10 to 15 years for peripheral 
revascularization; e.g. the Omniflow® II biosynthetic 
vascular graft (OBVG-II) (Bio Nova International Pty 
Ltd, Victoria, Australia), the ProCol bovine mesenteric 
vein graft (ProCol, Hancock Jaffe. Laboratories, USA), 
and the Dardik human umbilical vein graft (Dardik 
Biograft, Meadox Medicals, Inc., Oakland, N.J.).[7-9]
In general, conduits manufactured from ePTFE 
have demonstrated higher rates of thrombosis and 
infection, compared to biologically derived alternatives. 
Although concern of structural failure and aneurysmal 
degeneration in some biological grafts has limited 
their general use,[10] the OBVG-II has consistently 
demonstrated low rates of aneurysm formation.[11-13]
In this study, the OBVG-II biosynthetic graft 
was evaluated in cases of occlusive vascular disease. 
The aim of this study was to evaluate the early and 
long-term results of above- and below-knee femoro-
popliteal bypasses performed with OBVG-II in our 
clinical experience.
PATIENTS AND METHODS
This retrospective, observational, clinical study 
included a total of 93 patients (61 males, 32 females; 
mean age 56.9±7.4 years; range, 43 to 83 years) who 
underwent femoro-popliteal bypass in which the 
OBVG-II was used due to peripheral arterial disease 
between July 2006 and July 2016 at Department 
of Cardiovascular Surgery, Bursa Yüksek İhtisas 
Training and Research Hospital, Turkey. The study was 
approved by the local institutional Ethical Committee 
of University of Health Sciences. The study was 
conducted in accordance with the principles of the 
Declaration of Helsinki.
All data were retrospectively retrieved from the 
hospital medical files and included in the analysis. Data 
included age, gender, history of hypertension, diabetes 
mellitus, coronary artery disease, hyperlipidemia, 
smoking, and follow-up time. Laboratory parameters 
were studied from venous blood sample before surgery. 
All patients were clinically evaluated and arterial 
angiography and/or magnetic resonance angiography 
was performed. The patients with occlusive vascular 
disease symptoms were classified according to the 
Rutherford Classification scheme and the Trans-
Atlantic Inter-Society Consensus (TASC II) criteria 
were used for the angiographic evaluation. Patients 
with traumatic vascular injury were excluded from 
the study. The patency rates were evaluated using the 
information from medical charts, such as physical 
examination, medical imaging, and laboratory results. 
In our clinical practice, we prefer autogenous 
saphenous grafts in peripheral bypass operations. 
The reasons for the use of bioprosthetic grafts are 
as follows: (i) the lack of suitable saphenous veins, 
(ii) possible coronary artery bypass grafting in the 
future, (iii) the necessity for more distal peripheral 
bypass, and (iv) avoiding a second wide incision for 
vein harvesting in patients with impaired peripheral 
circulation. Over a 10-year (July 2006 - July 2016) 
period, OBVG-II 6-mm in internal diameter was used 
for lower extremity revascularization procedures.
Surgical technique
Surgery was performed under general or spinal 
anesthesia. A 6-mm OBVG-II was used in all patients. 
In the femoro-popliteal below-knee bypass (FemPop-
Bknee) group, distal anastomoses were performed by 
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adding about 4 to 5 cm long autogenous saphenous 
vein graft to OBVG-II. As a result, we created a 
composite graft. Intravenous heparin (100 IU/kg) was 
administered prior to anastomosis and the activated 
clotting time was maintained above 280 seconds. All 
anastomoses were made in an end-to-side fashion.
In the early postoperative period, a prophylactic dose 
of low-molecular-weight heparin (twice dose of 1 mg/kg 
enoxaparin sodium) was administered to all patients. 
On the second postoperative day, in cases with no 
contraindications, further anticoagulation was initiated 
with the antiplatelet (aspirin 300 mg or clopidogrel 
75 mg). Low-molecular-weight-heparin was continued, 
until antiplatelet or coumadin therapy reached effective 
levels. Coumadin was administered to only one patient 
with patent crural deep venous thrombosis. 
Postoperative follow-up was performed at first 
30 days, and every six months, and annually thereafter. 
The follow-up continued until death or no further 
communication was possible to the patient. In such 
cases, data from the last visit were used. In each 
visit, graft patency was assessed either by physical 
examination for the presence of a palpable graft pulse, 
and by Duplex scanning suspected graft occlusion was 
verified by arteriography.
Primary graft patency was defined as uninterrupted 
patency with no requirement for further surgical 
procedures on the graft or its anastomoses. Assisted 
patency was defined as blood flow through a graft that 
required reintervention to restore blood flow. Long-term 
results were analyzed in terms of graft patency.
Statistical analysis
Statistical analysis was performed using the IBM 
SPSS version 21.0 (IBM Corp., Armonk, NY, USA). 
Continuous and ordinal variables were expressed in 
mean ± standard deviation and nominal variables 
were expressed in frequency and percentage. The 
Kolmogorov-Smirnov test and Shapiro-Wilk tests 
of normality were used to identify distribution of 
variables. The chi-square test was used to compare 
two groups for nominal variables. The Mann-Whitney 
U test was used to compare two groups for continuous 
variables without normal distribution. Long-term 
results were analyzed by the Kaplan Meier curves, and 
differences in subgroups were assessed by the log-rank 
test. For all tests, a p value of <0.05 was considered 
statistically significant.
RESULTS
The patients were divided into two groups: a total of 
62 patients (64.5% male, mean age 57.4±8.3 years) 
undergoing femoro-popliteal above-knee bypass 
(FemPop-Aknee group) and 31 patients (67.7% 
male, mean age 56.1±6.6 years) undergoing the 
FemPop-Bknee group. The demographic and clinical 
properties of the subjects are summarized in Table 1. 
Table 1. Patient demographic and clinical features
Femoro-popliteal above-knee
bypass group (n=62)
Femoro-popliteal below-knee
bypass group (n=31)
n % Mean±SD n % Mean±SD p
Age (year) 57.4 ± 8.3 56.1 ± 6.6 0.327*
Gender
Male 40 64.5 21 67.7 0.758*
Hypertension 24 38.7 19 61.3 0.040*
Diabetes mellitus 37 59.7 18 58.1 0.881*
Coronary artery disease 27 43.5 8 25.8 0.096*
Smoking 38 61.3 19 61.3 1.000*
Hyperlipidemia 34 54.8 13 41.9 0.241*
Follow-up (months) 44.9±18.8 47.3±22.3 0.302‡
TASC II Femoro-popliteal
B
C
D
9
31
22
1
16
14
0.228*
Rutherford Grade
Grade 1
Grade 2
59
3
29
2
0.745*
SD: Standard deviation; TASC: TransAtlantic Inter-Society Consensus; * Pearson chi-Suquare; ‡ Mann-Whitney U test.
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Both FemPop-Aknee group and FemPop-Bknee group 
were similar. The occlusive vascular diseases of the 
patients were classified clinically as Rutherford grade 
and angiographic as the TASC II classification (Table 1). 
There were no signiﬁcant differences between two 
groups (p=0.745 according to Rutherford, p=0.228 
according to TASC II).
The mean follow-up was 44.9±18.8 months in the 
FemPop-Aknee group and 47.3±22.3 months in the 
FemPop-Bknee group (p=0.302). Nineteen patients 
were lost to long-term follow-up. The Kaplan-Meier 
curves, cumulative proportion surviving for FemPop-
Aknee group was 79%, for FemPop-Bknee group was 
80.6% (Log-rank; mental-cox; p=0.304) (Figure 1). In 
the first 20 postoperative days, three (3.2%) patients 
died of complications due to sepsis (in FemPop-
Aknee group, n=1), secondary hepatorenal failure 
due to ischemic reperfusion injury (in FemPop-Bknee 
group, n=1), and heart failure due to perioperative 
myocardial infarction (in FemPop-Bknee group, n=1). 
In the follow-up period, two (2.7%) patients died 
due to unrelated causes and 14 patients were lost to 
follow-up. 
Cumulative primary graft patency rates of FemPop-
Aknee and FemPop-Bknee groups for 3, 4, and 
5 years were 98% and 95%, 78% and 86%, and 75% 
and 45%, respectively (log-rank; p=0.312) (Figure 2). 
In total, there were 18 graft occlusions observed in the 
follow-up period. Secondary interventions performed 
on these patients were: graft thrombectomy in 
10 patients (55.5%), thrombectomy and graft revision 
in six patients (33.3%), and thrombolysis in two 
patients (11.1%). Cumulative assisted graft patency 
rates of FemPop-Aknee and FemPop-Bknee groups 
for five years were 87.9% and 65.3%, respectively 
(log-rank; p=0.530) (Figure 3).
Femoro-popliteal 
bypass
Months 36 48 60 96
Above-knee N. at risk
SE
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SE
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9
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1.0
0.8
0.6
0.4
0.2
0.0
0 40
Follow-up (months)
Survival function
C
um
 s
ur
vi
va
l
8020 60 100
p=0.302
Fem-pop above-knee bypass
Fem-pop below-knee bypass
Fem-pop above-knee bypass-censored
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Figure 1. Kaplan Kaplan-Meier curves, cumulative proportion 
surviving for FemPop-Aknee group and FemPop-Bknee group.
N: Number of the patients; SE: Standard error.
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Figure 2. Kaplan Kaplan-Meier curves, cumulative primary graft 
patency rates of FemPop-Aknee and FemPop-Bknee groups.
N: Number of the patients; SE: Standard error.
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Local complications in patients were superficial 
wound infection in five cases (5.4%), hemorrhage 
necessitating surgical investigation in four cases 
(4.3%), and edema in five cases (5.4%). In four cases 
(4.3%), postoperative graft thrombosis was observed 
within 24 hours. Three of these cases required graft 
thrombectomy and one required revision of the distal 
anastomosis in addition to thrombectomy.
There were only two (2.1%) graft infections after 
follow-up period. In both of these cases, the grafts 
were used in highly contaminated areas. One patient 
underwent FemPop-Aknee bypass had infection and 
ischemic wound along with unregulated diabetes 
mellitus, and died from sepsis in the early postoperative 
period from related complications. In the second case, 
there was a wide incision following FemPop-Bknee 
bypass and became infected. This patient underwent 
major amputation above the knee after removal of the 
graft. In addition to, one patient with FemPop-Bknee 
bypass and three patients with FemPop-Aknee bypass 
underwent amputation.
Two (2.2%) aneurysmal degeneration was found 
during follow-up. The first case had a distal anastomotic 
pseudoaneurysm following FemPop-Aknee bypass, 
and was repaired after six months. The second case 
had distal anastomotic aneurysm following FemPop-
Aknee bypass at 48 months of follow-up and was 
repaired with saphenous vein interposition.
DISCUSSION
The Omniflow II biosynthetic graft was originally 
developed with the aim to maximize the advantages 
of combining synthetic and biological graft 
components. The graft is produced by implanting 
polyester scaffolded silicone mandrels into sheep to 
induce a wound healing reaction that incorporates 
the polyester mesh. The tissue engineered construct 
is, then, cross-linked with glutaraldehyde to produce 
a non-antigenic vascular replacement conduit. Unlike 
other approaches, the incorporated polyester mesh 
provides structural stability to the wall and the blood 
flow surface, formed on the silicone mandrel is 
“smooth” and non-thrombogenic.[14] In a previous 
study, the OBVG-II was compared favorably with 
ePTFE in both femoro-popliteal and crural bypass.[11] 
In the above-knee position, this difference was not so 
evident. In a 274 case series where the Omniflow I and 
II grafts were applied, the patency rates after three 
years were reported as 61.9% in above-knee femoro-
popliteal bypass and 55.4% in below-knee bypass.[11] 
The superior results reported in our study may be due 
to the exclusive use of Omniflow II.
van der Slegt et al.[15] reported that for five years 
primary patency rates for ePTFE and great saphenous 
vein (GSV) in FemPop-Aknee bypass were 25% and 
60%. In FemPop-Bknee bypass, these rates were 
8% and 54%. In a study in which they compared 
autologous vein and ePTFE bypass procedures, Kurc 
et al.[16] reported five-year primary patency rates of 
65.2% and 36.3%, respectively. Mamode and Scott[17] 
in their Cochrane review reported that autologous vein 
was better than PTFE. In our study, we found that 
cumulative primary graft patency rates of FemPop-
Aknee and FemPop-Bknee groups for three, four, and 
five years were 98%, 78%, and 75% versus 95%, 86%, 
and 45%, respectively.
There are a lot of study using grafts such as alternative 
autologous conduit (arm vein, small saphenous vein, 
and composite vein), GSV and non-autologous conduit. 
The use of non-autologous conduit is associated with 
lower primary patency and higher rates of morbidities. 
Femoro-popliteal bypass Months 36 48 60
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Figure 3. Kaplan Kaplan-Meier curves, cumulative assisted graft 
patency rates of FemPop-Aknee and FemPop-Bknee groups.
N: Number of the patients; SE: Standard error.
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In earlier studies that used composite vein graft, the 
primary and secondary patency rates of OBVG-II 
after five years in below-knee positions are %48, and 
71%, respectively.[6,17] Karaca et al.[18] reported that 
the composite graft was added to the saphenous vein 
graft to PTFE in patients with limited distal run-off. 
In our study, the primary and assisted patency rates of 
OBVG-II after five years in below-knee positions were 
45% and 67.3%, respectively. Other potential factors 
influencing these results may be that we constructed 
composite grafts by adding saphenous vein grafts to 
the distal end of the Omniflow II graft in a number of 
the infrapopliteal distal bypasses cases.
Our results are favorably comparable with the 
83.7% primary patency in the above-knee position 
after three years as reported by Yoshida et al.[19] 
where only OBVG-II were also used. In our study, the 
primary patency rate was 98% the above-knee position 
after three years. Other studies also reported improved 
below-knee femoropopliteal bypass results with ePTFE 
grafts, when a distal vein cuff was used.[20]
In some configurations, potential kinking of 
autogenous conduits has led many surgeons to prefer 
prosthetic grafts to autogenous saphenous vein. The 
wall of the OBVG-II incorporates polyester mesh that 
provides more resistance to external compression than 
available in autogenous vein grafts. In our study, there 
was no restriction of blood flow due to kinking and 
compression. In the procedures with medium-sized 
vessels, diameter mismatch complications were not 
encountered.
Postoperative graft infection is a devastating 
complication of vascular surgery compromising both 
life and limb. Resistance to infection is an important 
property of a vascular graft. The ability to place a 
graft that can resist infection at the time of primary 
reconstruction or be placed in an infected field during a 
secondary revascularization is a great advantage. In our 
study, during a mean of 47.3±22.3 months follow-up, 
graft infection was observed in two (2.5%) cases. 
This case had wide infected area and was amputated. 
However, in a large study including 274 patients. Koch et 
al.[11] reported no infections with Omniflow. Nakajima et 
al.[21] reported two infections in 90 patients over a mean 
observation period of 38 months. Considering these 
findings, the Omniflow II biosynthetic graft provides 
a good, viable alternative in cases of infection or in 
patients where infections are likely to occur.
It was reported that the rate of aneurysmal 
dilatation in human umbilical vein grafts reinforced 
with an external Dacron mesh was 7% at three years.[10] 
By comparison, one (1.26%) aneurysmal dilatation was 
observed in this study with follow-up to a maximum 
of nine years. In a similar study, which is consistent 
with our findings, after one year follow-up period, 
aneurysmal dilatation was reported as 0%, while in 
a series of 318 cases, it was 2.6% over 10 years with 
a mean of 4.8 years.[13,16] Our findings suggest that 
this OBVG-II may be an acceptable alternative for 
above-knee femoropopliteal bypass and below-knee 
femoropopliteal bypass.
The major limitation of our study is the fact that 
only Omniflow II grafts were used in all cases. Larger 
series comparing the results with different types of 
synthetic vascular grafts in a randomized prospective 
setting are needed.
In conclusion, the Omniflow II biosynthetic bovine 
collagen vascular grafts provide a good alternative 
for lower limb reconstructive vascular procedures in 
medium and small sized arteries, when autogenous 
vein grafts are not available. The procedures reported 
in this study have provided acceptable levels of primary 
and secondary patency rates, showing high resistance 
to infection and no aneurysmal dilatation.
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